On December 20, 2021 EpiAxis Therapeutics reported that expanding its PKC theta pre-clinical program and sending its peptides to Icahn School of Medicine at Mount Sinai (Press release, EpiAxis Therapeutics, DEC 20, 2021, View Source;utm_medium=rss&utm_campaign=epiaxis-highlights-december-2021 [SID1234597691]).
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
Mt Sinai oncology
EpiAxis is collaborating with Dr Hanna Y Irie, MD, PhD, Associate Professor of Medicine, Hematology and Medical Oncology, Icahn School of Medicine at Mount Sinai and a leading research scientist in the PKC theta cancer sector. Under the collaboration, EpiAxis will provide Dr. Irie with its PKC theta inhibitors for evaluation in breast cancer models.
"This is an important collaboration for EpiAxis as we expand our pre-clinical program to advance our PKC theta assets," said EpiAxis CEO Dr Jeremy Chrisp. "We are delighted to be collaborating with Dr Irie’s team at the Icahn School of Medicine as this complements and strengthens our existing focus on LSD1 in breast cancer."
"This is an exciting opportunity to validate novel inhibitors against a promising therapeutic target for triple negative breast cancer, a particularly aggressive subtype that we have been studying for many years," said Mount Sinai’s Dr Irie about the partnership with EpiAxis.. "Once validated, we hope to translate these inhibitors for the benefit of patients."
EpiAxis CEO Jeremy Chrisp and Chairman David Fuller attended a Wholesale Investor networking event on December 16 at Verandah Bar in Sydney CBD.
The event was a valuable opportunity to share news about the company’s next generation therapeutics with an engaged audience.
"It was exciting to reveal how EpiAxis is spearheading a new approach to treating cancer," Dr Chrisp said.
Dr Chrisp explained to the attendees that while most existing therapies aim to destroy cancer cells, EpiAxis’ science reprograms them back into normal cells and increase cancer remission and its potential global impact. EpiAxis looks forward to expanding its partnership with Wholesale Investor in 2022.
"It was great to see like-minded professional investors, fund managers, family offices, and some of our clients at our WI Private event in Sydney," Wholesale Investor noted. "The Wholesale Investor team is truly grateful for the huge turnout and support – this has empowered us to create more engagement opportunities in the future."
EpiAxis also farewelled outgoing Director Nick McNaughton in mid-December.
"Thank you Nick for your six years of advice, counsel and support," Dr Chrisp said. "We wish you well with your next enterprise at Campus Plus."
McNaughton said: "It has been a great honour and privilege to represent all shareholders and stakeholders during my time on the Board of EpiAxis Therapeutics – the work Jeremy Chrisp, David Fuller and the extended team are doing is life changing. My oldest sister Val passed away from Breast Cancer in 1997 aged 49 and cancer remains the scourge of our time. It is my fervent belief that over the next decade we will find a cure to cancer and the work EpiAxis and the like are doing in this space will lead to the breakthrough discoveries that are needed to make this a reality."
Jeanette Wood will replace Nick as Director on the EpixAxis Board. Her board experience includes the successful listing of Nuevolution AG on the Swedish stock exchange and its recent takeover offer from Amgen.